No Data
Hybio Pharmaceutical: Performance forecast for the first quarter of 2025.
Hybio Pharmaceutical: 2024 Annual Performance Brief
Hybio Pharmaceutical (300199.SZ): Expected profit of 60 million to 72 million yuan in the first quarter, turning losses into profits year-on-year.
Gelonghui March 26丨Hybio Pharmaceutical (300199.SZ) announced its performance forecast for the first quarter of 2025. From January to March 2025, the company expects to achieve revenue of 0.29 billion yuan - -0.31 billion yuan, an increase of 93.00% - 106.31%; the net income attributable to shareholders of the listed company is expected to be a profit of 60 million yuan - 72 million yuan, compared to a loss of 14.102 million yuan in the same period last year; the net income after deducting non-recurring gains and losses is expected to be a profit of 55 million yuan - 67 million yuan. On December 23, 2024, the company reported liraglutide to the USA Food and Drug Administration.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Hybio Pharmaceutical (300199.SZ): Re-certified as a national high-tech enterprise.
On March 6th, Gelonghui reported that Hybio Pharmaceutical (300199.SZ) announced that recently, Shenzhen Hybio Pharmaceutical Co., Ltd. received the "High-tech Enterprise Certificate" (No.: GR202444201911) recognized by the office of the national high-tech enterprise recognition management leading group, jointly issued by the Shenzhen Municipal Bureau of Industry and Information Technology, the Shenzhen Municipal Finance Bureau, and the Shenzhen Municipal Taxation Bureau of the State Administration of Taxation. The certificate was issued on December 26, 2024, and is valid for three years.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
